217 related articles for article (PubMed ID: 24116135)
41. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.
Popelová O; Sterba M; Simůnek T; Mazurová Y; Guncová I; Hroch M; Adamcová M; Gersl V
J Pharmacol Exp Ther; 2008 Jul; 326(1):259-69. PubMed ID: 18434588
[TBL] [Abstract][Full Text] [Related]
42. Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.
Yan T; Deng S; Metzger A; Gödtel-Armbrust U; Porter AC; Wojnowski L
Mol Cancer Ther; 2009 May; 8(5):1075-85. PubMed ID: 19417146
[TBL] [Abstract][Full Text] [Related]
43. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
[TBL] [Abstract][Full Text] [Related]
44. The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II.
Hasinoff BB; Kuschak TI; Fattman CL; Yalowich JC
Anticancer Drugs; 1998 Jun; 9(5):465-71. PubMed ID: 9660545
[TBL] [Abstract][Full Text] [Related]
45. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Hofland KF; Thougaard AV; Sehested M; Jensen PB
Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
[TBL] [Abstract][Full Text] [Related]
46. DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation.
Dal Ben D; Palumbo M; Zagotto G; Capranico G; Moro S
Curr Pharm Des; 2007; 13(27):2766-80. PubMed ID: 17897022
[TBL] [Abstract][Full Text] [Related]
47. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.
Damiani RM; Moura DJ; Viau CM; Caceres RA; Henriques JAP; Saffi J
Arch Toxicol; 2016 Sep; 90(9):2063-2076. PubMed ID: 27342245
[TBL] [Abstract][Full Text] [Related]
48. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Henriksen PA
Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
[TBL] [Abstract][Full Text] [Related]
49. Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p.
Yu X; Ruan Y; Shen T; Qiu Q; Yan M; Sun S; Dou L; Huang X; Wang Q; Zhang X; Man Y; Tang W; Jin Z; Li J
Biomed Res Int; 2020; 2020():5107193. PubMed ID: 32190669
[TBL] [Abstract][Full Text] [Related]
50. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
51. Dexrazoxane abrogates acute doxorubicin toxicity in marmoset ovary.
Salih SM; Ringelstetter AK; Elsarrag MZ; Abbott DH; Roti EC
Biol Reprod; 2015 Mar; 92(3):73. PubMed ID: 25609833
[TBL] [Abstract][Full Text] [Related]
52. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.
Simůnek T; Stérba M; Popelová O; Adamcová M; Hrdina R; Gersl V
Pharmacol Rep; 2009; 61(1):154-71. PubMed ID: 19307704
[TBL] [Abstract][Full Text] [Related]
53. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
54. Thioredoxin Decreases Anthracycline Cardiotoxicity, But Sensitizes Cancer Cell Apoptosis.
Das KC; Muniyappa H; Kundumani-Sridharan V; Subramani J
Cardiovasc Toxicol; 2021 Feb; 21(2):142-151. PubMed ID: 32880787
[TBL] [Abstract][Full Text] [Related]
55. Grape seed proanthocyanidins ameliorate Doxorubicin-induced cardiotoxicity.
Li J; Liu H; Ramachandran S; Waypa GB; Yin JJ; Li CQ; Han M; Huang HH; Sillard WW; Vanden Hoek TL; Shao ZH
Am J Chin Med; 2010; 38(3):569-84. PubMed ID: 20503473
[TBL] [Abstract][Full Text] [Related]
56. Interaction model for anthracycline activity against DNA topoisomerase II.
Moro S; Beretta GL; Dal Ben D; Nitiss J; Palumbo M; Capranico G
Biochemistry; 2004 Jun; 43(23):7503-13. PubMed ID: 15182192
[TBL] [Abstract][Full Text] [Related]
57. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.
Plandé J; Platel D; Tariosse L; Robert J
Toxicol Lett; 2006 Feb; 161(1):37-42. PubMed ID: 16129573
[TBL] [Abstract][Full Text] [Related]
58. The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia.
Niitsu N; Higashihara M; Honma Y
Exp Hematol; 2002 Nov; 30(11):1273-82. PubMed ID: 12423680
[TBL] [Abstract][Full Text] [Related]
59. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
[TBL] [Abstract][Full Text] [Related]
60. Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
Smith TA; Phyu SM; Akabuogu EU
Anticancer Res; 2016 Jan; 36(1):87-93. PubMed ID: 26722031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]